Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q3 2026 · 10-Q
Revenue—
Net Income-$20.32M-$20.32MN/M vs Q3 2025 EPS Diluted-$0.15-$0.15N/M vs Q3 2025 Operating Income-$10,810,209N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
Operating Cash Flowderived-$21,010,522N/M ended Jun 30, 2026 · filed Aug 18, 2026 · 49 d after period end